Systematic review on randomized controlled trials of coronary heart disease complicated with depression treated with Chinese herbal medicines

An-lu Wang; Zhuo Chen; Jing Luo; Qing-hua Shang; Hao Xu

doi:10.1007/s11655-015-2110-9

Your Location：

Home >

Browse articles >

Systematic review on randomized controlled trials of coronary heart disease complicated with depression treated with Chinese herbal medicines

Updated：2021-08-27

- Systematic review on randomized controlled trials of coronary heart disease complicated with depression treated with Chinese herbal medicines
- Chinese Journal of Integrative Medicine Vol. 22, Issue 1, Pages: 56-66(2016)
- Affiliations：
  
  1. Graduate School, Beijing University of Chinese Medicine,Beijing,China
  2. Cardiovascular Diseases Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-015-2110-9
  CLC：
- Published：2016，
  
  Published Online：18 June 2015，
Scan for full text
Wang, Al., Chen, Z., Luo, J. et al. Systematic review on randomized controlled trials of coronary heart disease complicated with depression treated with Chinese herbal medicines., Chin. J. Integr. Med. 22, 56–66 (2016). https://doi.org/10.1007/s11655-015-2110-9

An-lu Wang, Zhuo Chen, Jing Luo, et al. Systematic review on randomized controlled trials of coronary heart disease complicated with depression treated with Chinese herbal medicines. [J]. Chinese Journal of Integrative Medicine 22(1):56-66(2016)
Wang, Al., Chen, Z., Luo, J. et al. Systematic review on randomized controlled trials of coronary heart disease complicated with depression treated with Chinese herbal medicines., Chin. J. Integr. Med. 22, 56–66 (2016). https://doi.org/10.1007/s11655-015-2110-9 DOI：

An-lu Wang, Zhuo Chen, Jing Luo, et al. Systematic review on randomized controlled trials of coronary heart disease complicated with depression treated with Chinese herbal medicines. [J]. Chinese Journal of Integrative Medicine 22(1):56-66(2016) DOI： 10.1007/s11655-015-2110-9.

摘要

This systemic review evaluated the efficacy and safety of Chinese herbal medicines (CHMs) in patients with coronary heart disease (CHD) complicated with depression. All databases were retrieved till September 30

2014. Randomized controlled trials (RCTs) comparing CHMs with placebo or conventional Western medicine were retrieved. Data extraction

analyses and quality assessment were performed according to the Cochrane standards. RevMan 5.3 was used to synthesize the results. Thirteen RCTs enrolling 1

095 patients were included. Subgroup analysis was used to assess data. In reducing the degree of depression

CHMs showed no statistic difference in the 4th week [mean difference (MD)=–1.06; 95% confidence interval (CI)–2.38 to 0.26; n=501; I2=73%]

but it was associated with a statistically significant difference in the 8th week (MD=–1.00; 95% CI–1.64 to–0.36; n=436; I2=48%). Meanwhile

the combination therapy (CHMs together with antidepressants) showed significant statistic differences both in the 4th week (MD=–1.99; 95% CI–3.80 to–0.18; n=90) and in the 8th week (MD=–5.61; 95% CI–6.26 to–4.97; n=242; I2=87%). In CHD-related clinical evaluation

3 trials reported the intervention group was superior to the control group. Four trials showed adverse events in the intervention group was less than that in the control group. CHMs showed potentially benefits on patients with CHD complicated with depression. Moreover

the effect of CHMs may be similar to or better than antidepressant in certain fields but with less side effects. However

because of small sample size and potential bias of most trials

this result should be interpreted with caution. More rigorous trials with larger sample size and higher quality are warranted to give high quality of evidence to support the use of CHMs for CHD complicated with depression.

Abstract

2014. Randomized controlled trials (RCTs) comparing CHMs with placebo or conventional Western medicine were retrieved. Data extraction

analyses and quality assessment were performed according to the Cochrane standards. RevMan 5.3 was used to synthesize the results. Thirteen RCTs enrolling 1

095 patients were included. Subgroup analysis was used to assess data. In reducing the degree of depression

CHMs showed no statistic difference in the 4th week [mean difference (MD)=–1.06; 95% confidence interval (CI)–2.38 to 0.26; n=501; I2=73%]

but it was associated with a statistically significant difference in the 8th week (MD=–1.00; 95% CI–1.64 to–0.36; n=436; I2=48%). Meanwhile

the effect of CHMs may be similar to or better than antidepressant in certain fields but with less side effects. However

because of small sample size and potential bias of most trials

关键词

Chinese Herbal Medicinecoronary heart diseasedepressionsystematic review

Keywords

Chinese Herbal Medicinecoronary heart diseasedepressionsystematic review

references

World Health Organization. Global status report on noncommunicable diseases 2010. Description of the global burden of NCDs, their risk factors and determinants. Geneva: World Health Organization; 2011:176.

WHO. 10 facts on the state of global health. Available at: http://www.who.int/features/factfiles/global_burden/en/

WHO. The overview of depression. Available at: http://www.who.int/mediacentre/factsheets/fs369/en/

Lett HS, Blumenthal JA, Babyak MA, Sherwood A, Strauman T, Robins C, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004;66:305–315.

Meijer A, Conradi HJ, Bos EH, Anselmino M, Carney RM, Denollet J, et al. Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data metaanalysis. Br J Psychiatry 2013;203:90–102.

van Melle JP, de Jonge P, Spijkerman TA, Tijssen JG, Ormel J, van Veldhuisen DJ, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 2004;66:814–822.

Zhang JM, Liang JZ, Gu NF. The interactions of antidepressant drugs. Chin J Clin Pharm (Chin) 2004;13:316–320.

World Health Organization. International statistical classification of diseases and related health problems (10th revision). Available at: http://www. who.int/classifications/icd/en/

Chinese Society of Psychiatry. Chinese classification of mental disorders. Jinan: Shandong Science and Technology Press; 2001:87–89.

Hamilton MJ. Neurology neurosurgery and psychiatry. 1960;23:56–62.

Cao ZD, Mao JL, Bao ZX. Treatment of depression in patients with CAD by therapy of nourishing Liver and Kidney. J Chengdu Univ Tradit Chin Med (Chin) 2006;29:25–28.

Cao ZD, Mao JL, Bao ZY, Wu SB. Clinical observation on the therapeutic effect of Tongxinluo Capsule on depression in patients with coronary heart disease. Chin J Difficult Complic Cases (Chin) 2006;5:251–253.

He JW, Hu QH, Li T, Wang LQ, Sun FJ, Wang BB. Observation of combination therapy of paroxetine and Xuefu Zhuyu Decoction on coronary heart disease complicating with depression in elder patients. Modern J Integr Tradit Chin West Med (Chin) 2013;22:3081–3082, 3092.

Li X, Tong LG. The effects of Jiawei Ganmai Dazao Decoction on treating 32-cases depression following percutaneous coronary intervention. Zhejiang J Tradit Chin Med (Chin) 2008;43(2):88–89.

Min XM. The therapeutic effect of Shensong Yangxin Capsule combined with deanxit in treatment of depression following myocardial infarction curative effect observation. Guide China Med (Chin) 2013;11:406–407.

Qin HW, Liu P. Coronary heart disease-related depression integrative medicine research. Acta Neuropharmacol (Chin) 2012;2:1–4

Shang XM, Zeng QM, Jing GG, Jiang LF, Wang H. The effects of Modified Chaihu Longgu Muli Decoction in treating 30 cases depression following percutaneous coronary intervention. Guid J Tradit Chin Med Pharm (Chin) 2014;20:43–44.

Shao J, Sun XZ. The observation on the therapeutic effect of Jieyu Decoction on depression in patients with coronary heart disease. Clin J Tradit Chin Med (Chin) 2007;19:12–13.

Shao J, Peng TT. The observation on the clinical effect of Shugan Jieyu Decoction on depression of coronary heart disease with ventricular arrhythmia. Chin J Basic Med Tradit Chin Med (Chin) 2009;15:964–965.

Yang JH. The observation on the clinical effect of Shugan Jieyu Decoction on 66-cases depression of coronary heart disease. Guid J Tradit Chin Med Pharm (Chin) 2010;16:22–24.

Zhang LF. Syndrome characteristics and Chinese medicine intervention clinical research of coronary heart disease combine with depression [dissertation]. Beijing: Beijing University of Traditional Chinese Medicine; 2011.

Zhu F. The clinical research of Jieyu particle in treatment of unstable angina patients with depression status [dissertation]. Jinan: Shandong University of Traditional Chinese Medicine; 2008.

Ni DM, Ban WM, Wang CL, Chen GR, Fu XK, Ma YQ, et al. Clinical research on Shuxin Jieyu decoction treating coronary heart disease with depression. J Emerg Tradit Chin Med (Chin) 2014;23:835–836, 843.

Jiao Y, Li SW, Shang QH, Xu H. Multifactor dimensionality reduction analysis of the correlation of Chinese medicine syndrome evolvement and cardiovascular events in patients with stable coronary heart disease. Chin J Integr Med 2014;20:341–346.

Liu HX, Wang ZY. 113 patients with coronary angiography syndromes and imaging characteristics analysis. J China-Japan Friendship Hosp (Chin) 2006;20:37.

Yu G, Wang J. Blood stasis syndrome of coronary heart disease: a perspective of modern medicine. Chin J Integr Med 2014;20:300–306.

Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: Greater precision but with greater uncertainty. JAMA 2003;289:2554–2559.

Kjaergard LL, Villumsen J, Gluud C. Reported methodological quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med 2001;135:982–989.

Dobs G, Tao I. The model of Western integrative medicine: the role of Chinese medicine. Chin J Integr Med 2011;17:11–20.

Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726–732.

Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann of Intern Med 2006;144:364–367.

Xing L, Robinson N. Methodological approaches to developing and establishing the body of evidence on postmarketing Chinese medicine safety. Chin J Integr Med 2013;19:494–497.

Wang JY. Significance of evidence-based medicine in the assessment of Chinese medicine clinical efficacy. Chin J Integr Med 2010;16:392–393.

Chen KJ, Song J. The raising of evidence-based medicine inspires the integration of traditional and Western medicine. Chin J Integr Med 2000;6:242–243.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Is Chinese herbal medicine effective for elderly isolated systolic hypertension? A systematic review and meta-analysis

Chinese Herbal Medicine Xingnaojing Injection (醒脑静注射液) for Hypoxic Ischemic Encephalopathy in Newborns: A Systematic Review and Meta-Analysis

A systematic review and meta-analysis of type 2 diabetes mellitus treatment based on the “three-typed syndrome differentiation” theory in Chinese medicine

Pinching spine: A potential treatment for depression

Effects of Kaixin Jieyu Decoction (开心解郁汤) on behavior, monoamine neurotransmitter levels, and serotonin receptor subtype expression in the brain of a rat depression model

Related Author

No data

Related Institution

Department of Cardiovascular Diseases, Guang’anmen Hospital, China Academy of Chinese Medical Sciences

Gerontology Medical Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences

Department of Pharmacy, Evidence-Based Pharmacy Centre, West China Second Hospital, Sichuan University

West China Second Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University

Department of Pediatrics, West China Second Hospital, Sichuan University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰